Loading patent…
OwnerHilde Azijn, Marie-Pierre De Bethune +1inventors
InventorsHilde Azijn, Marie-Pierre De Bethune, Johan Vingerhoets
Estimating the term…
The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis
A computer system comprising at least one database correlating the presence of at least one mutation in a human immunodeficiency virus (HIV) reverse transcriptase and a change in susceptibility of at least one strain of HIV to a reverse transcriptase inhibitor, comprising at least one record corresponding to a correlation between at-least one mutation 386A in said reverse transcriptase, and treatment with at least a reverse transcriptase inhibitor.
A method of evaluating the effectiveness of a reverse transcriptase inhibitor as an antiviral therapy for a patient infected with at least one mutant HIV strain comprising:
A method of identifying a drug effective against mutant HIV reverse transcriptase, comprising:
A method of identifying a drug effective against mutant HIV reverse transcriptase, comprising:
A method for evaluating a change in viral drug susceptibility, comprising:
A method of evaluating a change in viral drug susceptibility, comprising:
A method for evaluating a change in drug effectiveness against mutant HIV reverse transcriptase, comprising:
A vector for performing phenotypic analysis comprising an HIV sequence having at least one mutation 386A in the HIV reverse transcriptase gene.
An isolated and purified HIV reverse transcriptase sequence having at least one mutation 386A, wherein said at least one mutation in said sequence correlates to a fold change in susceptibility towards a HIV reverse transcriptase inhibitor.
An isolated and purified oligonucleotide comprising a HIV reverse transcriptase sequence of 5 to 100 bases for in vitro diagnosis of viral drug resistance, characterized in that said oligonucleotide comprises at least one mutation 386A.
Dependencies are inferred from the claim text.